目的 研究盐酸曲美他嗪胶囊联合阿托伐他汀钙片对冠心病患者血小板活化功能和血管内皮功能的影响。方法 选择2015年1月-2017年12月平顶山市第二人民医院收治的153例冠心病患者，随机分为两组。对照组口服阿托伐他汀钙片进行治疗，观察组在对照组的基础上联合口服盐酸曲美他嗪胶囊进行治疗。两组均治疗90 d。比较两组临床疗效、治疗前后的血小板活化功能和血管内皮功能指标改变情况。结果 观察组的有效率明显高于对照组，差异有统计学意义（P<0.05）。两组治疗后的α颗粒膜蛋白140（GMP-140）以及血管性假性血友病因子（vWF）水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后观察组的GMP-140、vWF水平明显低于对照组，差异有统计学意义（P<0.05）。两组治疗后的血浆内皮素水平明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后观察组明显低于对照组，差异有统计学意义（P<0.05）。结论 盐酸曲美他嗪胶囊联合阿托伐他汀钙片治疗冠心病患者可以有效发挥抑制血小板活化、改善内皮细胞损伤的效果。

Objective To investigate the clinical effect of Atorvastatin Calcium Tablets combined with Trimetazidine Hydrochloride Capsules on platelet activation and endothelial function in patients with coronary heart disease. Methods Selected 153 cases of patients with coronary heart disease who were treated in our hospital from January 2015 to December 2017, divided into two groups randomly. The control group oral Atorvastatin Calcium Tablets, observation group combined with Trimetazidine Hydrochloride Capsules. Platelet activation and vascular endothelial function in two groups before and after treatment were compared.Results The effective rate of the observation group was significantly higher than control group (P<0.05). After treatment, the levels of GMP-140 and vWF were significantly decreased (P<0.05), and the levels of GMP-140 and vWF in the observation group were significantly lower than control group (P<0.05). The plasma endothelin level of the two groups decreased significantly after treatment (P<0.05), and the observation group was more significant (P<0.05). Conclusion s Atorvastatin Calcium Tablets combined with Trimetazidine Hydrochloride Capsules can effectively inhibit platelet activation and improve endothelial cell injury in patients with coronary heart disease.